Lantheus Holdings stock has delivered very strong returns over the past few years, yet the current price sits close to the agreed cash offer from Curium, which raises questions about how much upside is left in the valuation.

• Over the past 5 years, Lantheus Holdings has returned about 294.0%, which puts recent share price moves into the context of a very strong multi year run.
• The agreed Curium acquisition, with a headline value of up to US$8b tied to milestones, can anchor expectations for the share price, while the long timetable and deal completion risks may cap how much investors are willing to pay above the upfront cash component.
• Lantheus Holdings scores highly on Simply Wall St's valuation checks, with 5 of 6 indicators pointing to the stock still screening as undervalued against its fundamentals.

The issue now is whether Lantheus Holdings offers enough valuation upside between today’s price and the full potential deal consideration to justify the risks around the transaction and the timetable involved.

Is Lantheus Holdings a Bargain on Earnings?

The P/E ratio is a useful cross check for Lantheus Holdings because it ties the share price directly to current earnings rather than long term forecasts. Lantheus Holdings trades on a P/E of about 23.6x, which is below both the Medical Equipment industry average of roughly 29.0x and the peer group average of about 49.7x. That already puts the stock at a discount to many other earnings generating healthcare companies.

The fair P/E ratio for Lantheus Holdings is estimated at around 26.8x, based on its own earnings profile, margins, industry and risk characteristics. This is modestly higher than the current multiple, which suggests the market is pricing the stock a little lower than this framework implies. Despite the agreed Curium deal anchoring attention on the cash offer, the current P/E still indicates that Lantheus Holdings is not being priced at a premium to its sector or peers.

On the P/E multiple, Lantheus Holdings stock appears undervalued relative to both its tailored fair ratio and broader industry benchmarks.

The Lantheus Holdings Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Lantheus Holdings pick up where this valuation puzzle leaves off. They explain what combination of future growth, margins and earnings would need to occur for Lantheus Holdings' stock to be worth materially more or less than today's price. Each narrative sets out a fair value as a thesis about the business that you can track over time, rather than a one off snapshot. These are available on Simply Wall St's Community page.

One of the top community narratives on Lantheus Holdings: roughly fairly valued

"Multiple new product launches within the next 18 months including the new F-18 PSMA PET, MK-6240, OCTEVY, and PNT2003 are set to diversify the revenue base…"

Do you think there's more to the story for Lantheus Holdings? Head over to our Community to see what others are saying!

The Bottom Line

Lantheus Holdings still screens as undervalued on current market multiples, even with the Curium offer framing expectations. The core question now is whether that discount reflects mispricing or a reasonable buffer for deal risk, timing and execution around the product pipeline. For investors, the crux is whether the current P/E re-rates closer to peers or stays pinned near the cash component of the transaction. That single issue is likely to define whether the existing valuation gap closes or persists.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.